First and Only Biologic Therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying
Type 2 inflammation (including
Atopic Dermatitis and
Asthma)
1,2
Now locally approved for:
-
Adult & adolescent (aged 12-17) patients with
moderate-to-severe atopic dermatitis who are candidates for systemic therapy
1
- An add-on maintenance treatment for
patients (12+ years) with inadequately controlled
severe asthma with type 2 inflammation
1
References:
1. DUPIXENT Summary of Product Characteristics. May 2020.
2. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.
SANOFI HONG KONG LIMITED
1/F & Section 212 on 2/F, AXA Southside, 38 Wong Chuk Hang Road, Hong Kong
Tel: (+852) 2506 8333 • Fax: (+852) 2506 2537